Peptonic Medical AB has entered into a partnership with Fermata Inc. in Japan

Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the company has entered into an agreement with fermata Inc. for the Japan market. The agreement concerns VagiVital®️ and Lunette®️.

The agreement concerns early registrations and non-exclusive commercial introduction of VagiVital®️ and Lunette®️ into the Japan market. fermata Inc. has confirmed the regulatory clearance to introduce VagiVital®️ in Japan in September. Lunette®️ will be introduced later in the year. With a successful introductory business build up the parties have agreed to enter into a discussion about a possible exclusive partnership for Japan at a later stage.

fermata Inc. business model is to act as an engine for the Asian femtech ecosystem, with teams based in Japan and Singapore. fermata Inc. supports in regulatory processes as well as in investments and early introductions in women´s health market channels; driven by concept stores, retail and online business.

– The fermata team will test the marketability of VagiVital in their own concept stores as well as selected retail partners. It will be exciting to work with Fermata in this introductory phase and hopefully the cooperation shall be successful and expand further, says Erik Sundquist, CEO of Peptonic

– We are excited to introduce VagiVital®️ and Lunette®️ into the asian market! VagiVital ®, especially, has a great potential for the Japanese market since there is no similar product of this quality. We hope that the collaboration with Peptonic and the introduction of their products will bring in a new insight into the women’s health market in Japan, says Amina Sugimoto, CEO of fermata.

For more information, please contact;
Erik Sundquist, CEO
Mobile: +46 722 49 90 43

This is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at August 20, 2021.

About VagiVital® AktivGel

VagiVital® AktivGel is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital® AktivGel was launched in Sweden as a non-prescription self-care product in July 2018. In April 2021 VagiVital® Moisturizing V Cleanser was added under the VagiVital® brand. (see

About Peptonic Medical AB

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research, develops and sells products in the field of women’s health. Our vision is to offer safe and effective treatments for women-specific diseases, medical conditions and well being. Peptonic Medical launched VagiVital® AktivGel in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness. The company’s development program also includes Vagitocin® – a product that contains oxytocin for the treatment of vaginal atrophy. The development of Vagitocin® has been put on hold.

The company was founded in 2009 and the share has been traded since 2014 on Spotlight (, short code: PMED) in Stockholm.

Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of Peptonic Medical. The company’s business concept is to lead a menstrual revolution in a positive spirit. By focusing on sustainable development, environmental issues and the promotion of sexual health, the company is evolving taking the lead as a green intimate care company. For more information about Lunette®, visit